Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04690608
Other study ID # 2412SS
Secondary ID
Status Not yet recruiting
Phase Early Phase 1
First received
Last updated
Start date December 1, 2024
Est. completion date February 1, 2025

Study information

Verified date March 2024
Source Tanta University
Contact Amin E Nawar, Lecturer
Phone 00201140095692
Email nawar20012002@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prospective interventional study on 60 eyes of resistant diabetic macular edema and central retinal vein occlusion that will receive suprachoroidal injection of Triamcinolone Acetonide (SCTA).


Description:

Read more »
Read more »

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1
suprachoroidal injection of the drug in cases of resistant diabetic macular edema and central retinal vein occlusion

Locations

Country Name City State
Egypt Tanta University Tanta El Gharbia

Sponsors (1)

Lead Sponsor Collaborator
Tanta University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Improvement of central macular thickness Reduction of the central macular thickness below 300 um 1 month
Secondary improved vision Improvement of best corrected visual acuity 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT05130385 - High Resolution Optical Coherence Tomography
Completed NCT01273727 - Ozurdex for Macular Edema Post Membrane Peeling Phase 2/Phase 3
Recruiting NCT04501367 - Assessing the Efficacy and Safety fo DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert(s) for the Treatment of Pain, Inflammation, and Cystoid Macular Edema Following 27 Gauge Vitrectomy With Internal Limiting Membrane Peel for the Treatment of Retinal Edema Associated With Macular Pucker. Phase 4
Completed NCT01847638 - Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery N/A